Plant Name: Thuja standishii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD3; DRD2; | |
| HDAC3; HDAC8; HDAC1; HDAC2; HDAC6; HDAC10; | |
| ALPL; AKR1B10; AKR1B1; HSD17B10; | |
| ACHE; GAA; | |
| KCNH2; | |
| AKT1; MET; AXL; NEK6; PKN1; MAPK1; PIM1; NEK2; PLK1; KDR; SRC; IGF1R; PTK2; AURKB; NUAK1; ALK; | |
| CA2; CA12; CA9; CA1; CA14; CA7; CA4; CA6; | |
| HIF1A; NFKB1; | |
| MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
| Histone deacetylase | HDAC8 | Histone deacetylase 8 | Q9BY41 | CHEMBL3192 |
| Histone deacetylase | HDAC1 | Histone deacetylase 1 | Q13547 | CHEMBL325 |
| Histone deacetylase | HDAC2 | Histone deacetylase 2 | Q92769 | CHEMBL1937 |
| Histone deacetylase | HDAC6 | Histone deacetylase 6 | Q9UBN7 | CHEMBL1865 |
| Histone deacetylase | HDAC10 | Histone deacetylase 10 | Q969S8 | CHEMBL5103 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0032041; NAD-dependent histone deacetylase activity (H3-K14 specific) | 3.335E-14 | 1.453E-10 | HDAC1, HDAC10, HDAC2, HDAC3, HDAC6, HDAC8 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.120E-14 | 1.495E-10 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.082E-12 | 1.963E-09 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0070932; histone H3 deacetylation | 2.758E-12 | 3.754E-09 | HDAC1, HDAC10, HDAC2, HDAC3, HDAC6, HDAC8 |
| MF | GO:0005488; binding | GO:0042826; histone deacetylase binding | 3.222E-09 | 1.276E-06 | HDAC1, HDAC10, HDAC2, HDAC3, HDAC6, HIF1A, PKN1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.812E-09 | 1.431E-06 | AURKB, CA2, CA7, DRD2, DRD3, HDAC8, HIF1A, KDR, MAPK1, NEK2, SRC |
| BP | GO:0008152; metabolic process | GO:0010870; positive regulation of receptor biosynthetic process | 6.300E-09 | 2.144E-06 | HDAC1, HDAC2, HDAC6, HIF1A |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.326E-09 | 2.417E-06 | HDAC6, HDAC8, HIF1A, KDR, MAPT |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.600E-08 | 7.450E-06 | AURKB, CA2, CA7, DRD2, DRD3, HIF1A, MAPK1, NEK2 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 3.105E-08 | 8.504E-06 | AKT1, ALK, AURKB, AXL, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PLK1, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 3.426E-08 | 9.185E-06 | AKT1, ALK, AURKB, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1, PLK1 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 6.128E-08 | 1.415E-05 | AKT1, AURKB, MAPK1, NEK6, PKN1, PLK1, SRC |
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 2.244E-07 | 4.249E-05 | ALK, AXL, IGF1R, KDR, MET |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.522E-07 | 4.586E-05 | AKR1B1, AKT1, DRD2, DRD3, HDAC1, HDAC2, HIF1A, IGF1R, KDR, MAPK1, PIM1, PTK2 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 2.788E-07 | 4.856E-05 | DRD2, DRD3, HDAC1, HDAC2 |
| BP | GO:0009987; cellular process | GO:0010639; negative regulation of organelle organization | 4.130E-07 | 6.813E-05 | AKT1, HDAC6, HDAC8, MAPT, MET, NEK2, PLK1, SRC |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 5.922E-07 | 9.211E-05 | AURKB, DRD3, HDAC6, HIF1A, KDR, MAPK1, MAPT, MET, NEK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0035094; response to nicotine | 1.844E-06 | 2.348E-04 | DRD2, HDAC2, MAPK1, NFKB1 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.218E-06 | 3.829E-04 | IGF1R, KDR, PTK2, SRC |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 5.508E-06 | 5.879E-04 | CA2, CA7, DRD2, DRD3, KDR, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 6.075E-06 | 6.391E-04 | DRD2, DRD3, HDAC1, HDAC2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 6.364E-06 | 6.630E-04 | AURKB, MAPK1, NEK2 |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 8.904E-06 | 8.935E-04 | AKT1, HDAC3, MAPK1, PLK1, SRC |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 9.209E-06 | 9.156E-04 | AKR1B1, AXL, HDAC2, HDAC6 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 9.619E-06 | 9.478E-04 | AKT1, ALPL, HDAC2, HDAC8, MAPK1, NFKB1, SRC |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.237E-05 | 1.161E-03 | CA2, HDAC3, SRC |
| BP | GO:0008152; metabolic process | GO:2000757; negative regulation of peptidyl-lysine acetylation | 1.237E-05 | 1.161E-03 | HDAC1, HDAC2, HDAC8 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.340E-05 | 1.247E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 1.383E-05 | 1.255E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 1.255E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.421E-05 | 1.279E-03 | AKT1, HIF1A, NFKB1, SRC |
| BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 1.536E-05 | 1.349E-03 | HDAC3, HDAC6, HDAC8, MAPK1, PLK1, SRC |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.699E-05 | 1.462E-03 | AKT1, AXL, CA2, DRD2, HDAC1, HDAC2, HIF1A, KDR, MAPT, NFKB1 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.784E-05 | 1.527E-03 | AXL, KDR, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.801E-05 | 2.194E-03 | ALPL, AXL, HDAC1, HDAC2, NFKB1, SRC |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 2.845E-05 | 2.220E-03 | AKR1B1, AKT1, HDAC8, SRC |
| BP | GO:0050896; response to stimulus | GO:0070848; response to growth factor | 2.917E-05 | 2.268E-03 | AKT1, HDAC2, HDAC6, KDR, MAPK1, SRC |
| MF | GO:0005488; binding | GO:0051059; NF-kappaB binding | 3.015E-05 | 2.328E-03 | HDAC1, HDAC2, HDAC3 |
| BP | GO:0050896; response to stimulus | GO:0070482; response to oxygen levels | 3.692E-05 | 2.744E-03 | AKT1, DRD2, HDAC1, HDAC2, HIF1A, SRC |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 3.841E-05 | 2.823E-03 | AKT1, AURKB, HDAC1, HDAC2, NUAK1 |
| BP | GO:0008152; metabolic process | GO:0000122; negative regulation of transcription from RNA polymerase II promoter | 3.890E-05 | 2.843E-03 | AURKB, DRD3, HDAC1, HDAC10, HDAC2, HDAC3, HDAC8, NFKB1, PLK1 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 3.922E-05 | 2.853E-03 | ACHE, HDAC1, HDAC2, HDAC6, IGF1R, KDR, MAPT, PIM1, PLK1, SRC |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 4.596E-05 | 3.187E-03 | DRD2, DRD3 |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 5.458E-05 | 3.691E-03 | AURKB, MAPK1, NEK2 |
| BP | GO:0065007; biological regulation | GO:0032147; activation of protein kinase activity | 5.638E-05 | 3.777E-03 | AKT1, ALK, DRD2, MAPK1, PKN1, SRC |
| BP | GO:0071840; cellular component organization or biogenesis | GO:0070841; inclusion body assembly | 6.885E-05 | 4.423E-03 | HDAC6, MAPT |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 6.885E-05 | 4.423E-03 | CA1, CA2 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 8.489E-05 | 5.312E-03 | AKR1B1, AKT1, IGF1R, NFKB1, SRC |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 9.432E-05 | 5.868E-03 | AKT1, AXL, MAPK1, SRC |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 1.034E-04 | 6.222E-03 | AKT1, AURKB, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0006584; catecholamine metabolic process | 1.110E-04 | 6.570E-03 | AKR1B1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 1.126E-04 | 6.643E-03 | AKT1, AXL, HDAC2, HDAC8, NFKB1, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 1.190E-04 | 6.964E-03 | AKT1, HIF1A, KDR |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 1.238E-04 | 7.228E-03 | AKT1, MAPT, MET, NEK2 |
| BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 1.252E-04 | 7.249E-03 | AKT1, DRD3, HDAC3, NFKB1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0044597; daunorubicin metabolic process | 1.282E-04 | 7.249E-03 | AKR1B1, AKR1B10 |
| BP | GO:0008152; metabolic process | GO:0044598; doxorubicin metabolic process | 1.282E-04 | 7.249E-03 | AKR1B1, AKR1B10 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 1.282E-04 | 7.249E-03 | DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.264E-04 | 7.249E-03 | ACHE, AKT1, ALK, DRD2, IGF1R, KCNH2, KDR, MAPK1, MAPT, MET, NFKB1, PLK1 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 1.282E-04 | 7.249E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0071356; cellular response to tumor necrosis factor | 1.364E-04 | 7.597E-03 | AKT1, HDAC1, MAPK1, NFKB1 |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 1.505E-04 | 8.235E-03 | DRD2, DRD3, HIF1A, MAPK1, MAPT |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.544E-04 | 8.408E-03 | DRD2, DRD3, HIF1A |
| BP | GO:0009987; cellular process | GO:0019896; axonal transport of mitochondrion | 1.646E-04 | 8.740E-03 | HIF1A, MAPT |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 1.799E-04 | 9.437E-03 | AKT1, ALK, HDAC2, MAPK1, NFKB1, PIM1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.565E-18 | 3.408E-14 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.464E-18 | 6.339E-16 | CA12; CA1; CA2; CA4; CA7; CA6; CA9; CA14 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.485E-10 | 2.475E-08 | HDAC2; HDAC3; HDAC10; SRC; HDAC1; MAPK1; HDAC8; NFKB1; HDAC6 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 3.204E-09 | 1.517E-07 | HDAC2; HDAC3; HDAC10; HDAC1; MAPK1; DRD2; HDAC8; HDAC6 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.615E-09 | 2.447E-07 | SRC; KDR; AKT1; MAPK1; HIF1A; MET; PTK2; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.728E-09 | 1.679E-07 | HDAC2; HDAC3; SRC; HDAC1; AKT1; MAPK1; HIF1A |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.092E-07 | 2.584E-06 | HDAC2; HDAC1; AKT1; MAPK1; HIF1A; MET; NFKB1; PTK2; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.742E-07 | 3.429E-06 | SRC; KDR; AKT1; MAPK1; PTK2 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.932E-07 | 3.429E-06 | SRC; KDR; AKT1; MAPK1; MET; PTK2; IGF1R |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.597E-07 | 4.098E-06 | SRC; KDR; AKT1; MAPK1; DRD2; MET; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.685E-07 | 6.049E-06 | KDR; AKT1; MAPK1; PKN1; MET; PTK2; NFKB1; IGF1R |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.316E-07 | 6.049E-06 | HDAC2; HDAC1; AKT1; MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.402E-06 | 2.624E-05 | AKT1; MAPK1; HIF1A; NFKB1; IGF1R |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.960E-06 | 2.319E-05 | HDAC2; HDAC1; MET; NFKB1; PTK2; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.460E-06 | 7.063E-05 | KDR; AKT1; MAPK1; MET; NFKB1; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.120E-06 | 6.208E-05 | PIM1; AKT1; MAPK1; NFKB1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 9.740E-06 | 8.645E-05 | HDAC2; HDAC1; AKT1; IGF1R |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.102E-05 | 9.201E-05 | AKT1; MAPK1; MET; HIF1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.474E-05 | 1.101E-04 | AKT1; MAPK1; MET; IGF1R |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.170E-05 | 9.228E-05 | AKT1; MAPK1; MET; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.558E-05 | 1.106E-04 | SRC; AKT1; MAPK1; NFKB1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.295E-05 | 2.075E-04 | SRC; AKT1; MAPK1; PTK2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.604E-05 | 2.132E-04 | AKT1; MAPK1; NFKB1; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.737E-05 | 1.175E-04 | SRC; MAPK1; MET; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.352E-05 | 2.472E-04 | SRC; AKT1; MAPK1; NFKB1; PTK2 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.917E-05 | 3.112E-04 | PIM1; AKT1; MAPK1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.259E-05 | 2.872E-04 | PLK1; AKT1; MAPK1; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.459E-04 | 1.164E-03 | SRC; AKT1; MAPK1; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.720E-04 | 8.722E-04 | PLK1; AKT1; MAPK1; IGF1R |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.787E-04 | 1.536E-03 | HDAC1; PIM1; MAPK1; MET; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.209E-04 | 1.082E-03 | ALK; AKT1; MAPK1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.436E-04 | 1.478E-03 | AKT1; MAPK1; IGF1R |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.711E-04 | 1.242E-03 | AKT1; MAPK1; HIF1A |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 5.214E-04 | 1.948E-03 | SRC; AKT1; MAPK1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.919E-04 | 2.677E-03 | AKT1; MAPK1; DRD2; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.594E-04 | 1.501E-03 | AKT1; MAPK1; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.373E-04 | 2.702E-03 | HDAC2; HDAC1; AKT1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.835E-04 | 1.856E-03 | AKT1; MAPK1; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.925E-04 | 1.548E-03 | SRC; MET; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.436E-04 | 1.478E-03 | SRC; MAPK1; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 7.807E-04 | 2.677E-03 | AKT1; NFKB1; PTK2 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.871E-04 | 2.138E-03 | SRC; MET; PTK2 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.011E-03 | 3.189E-03 | AKT1; NFKB1; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.174E-03 | 3.547E-03 | SRC; AKT1; MAPK1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.244E-03 | 3.680E-03 | AKT1; MAPK1; HIF1A |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.807E-04 | 2.677E-03 | MAPK1; PKN1; NFKB1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 8.347E-04 | 2.702E-03 | SRC; MAPK1; DRD2 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.975E-03 | 5.023E-03 | AKT1; MAPK1; MAPT; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.361E-05 | 2.075E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.632E-03 | 4.372E-03 | ACHE; AKT1; MAPK1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.353E-03 | 3.843E-03 | AKT1; MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.429E-03 | 3.980E-03 | AKT1; MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.590E-03 | 4.341E-03 | AKT1; MAPK1; NFKB1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.090E-03 | 5.029E-03 | SRC; KDR; MET; IGF1R |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.353E-03 | 3.843E-03 | AKT1; MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.943E-03 | 5.023E-03 | AKT1; MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.039E-03 | 5.023E-03 | AKT1; MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.039E-03 | 5.023E-03 | AKT1; MAPK1; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.137E-03 | 5.058E-03 | SRC; AKT1; MAPK1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.188E-03 | 5.092E-03 | PLK1; MAPK1; IGF1R |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.156E-03 | 6.591E-03 | AKT1; MAPK1; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.504E-03 | 5.557E-03 | AKT1; DRD2; DRD3 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.239E-03 | 5.127E-03 | HDAC2; HDAC1; PLK1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.396E-03 | 5.400E-03 | MAPK1; MET; PTK2 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.673E-03 | 5.751E-03 | AKT1; MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.731E-03 | 5.788E-03 | AKT1; MAPK1; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 3.285E-03 | 6.761E-03 | AKT1; MAPK1; IGF1R |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.885E-03 | 1.114E-02 | AKT1; MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.256E-03 | 1.022E-02 | MAPK1; MAPT; HSD17B10 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.020E-02 | 1.761E-02 | SRC; MAPK1; PTK2 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.794E-02 | 4.457E-02 | AKT1; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.199E-02 | 3.549E-02 | AKT1; NFKB1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.871E-02 | 3.055E-02 | NFKB1; PTK2 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.567E-02 | 2.617E-02 | SRC; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.632E-02 | 2.695E-02 | AKT1; MAPK1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 8.984E-03 | 1.595E-02 | AKT1; MAPK1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.030E-02 | 1.761E-02 | MAPK1; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 9.499E-03 | 1.665E-02 | AKT1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.084E-02 | 1.833E-02 | MAPK1; NFKB1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 7.055E-03 | 1.284E-02 | MAPK1; IGF1R |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 7.517E-03 | 1.351E-02 | AKT1; MAPK1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 6.829E-03 | 1.259E-02 | AKR1B10; AKR1B1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.341E-03 | 1.025E-02 | AKT1; MAPK1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.387E-03 | 1.193E-02 | MAPK1; NFKB1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.756E-03 | 9.380E-03 | DRD2; NFKB1 |
| hsa04330 | Notch signaling pathway_Homo sapiens_hsa04330 | 4.568E-03 | 9.136E-03 | HDAC2; HDAC1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.352E-03 | 6.799E-03 | SRC; MAPK1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.052E-03 | 5.023E-03 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.059E-03 | 3.270E-03 | CA2; CA4 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.592E-03 | 5.663E-03 | AKR1B10; AKR1B1 |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 2.901E-02 | 4.577E-02 | ALPL |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; ACHE; ACHE; ACHE; MAPT |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | HDAC2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; DRD2; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; KDR; PLK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; DRD2; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| NA: NA | Hyperaemia | NA | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; HIF1A; CA9; PLK1 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; IGF1R; DRD2; KDR; KDR; KDR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| C00-D49: Neoplasms | AML | NA | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD2; ACHE |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; DRD2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| NA: NA | Vomiting | NA | DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | PLK1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; AXL; DRD2; KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD2; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; DRD2; DRD2; DRD2; DRD2 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | PLK1; AURKB |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; HIF1A; MET; HDAC8; CA1; CA9; IGF1R; MAPK1; NFKB1; HDAC10; PIM1; SRC; KDR; ACHE; PLK1; PTK2; HDAC6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; DRD2 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; HIF1A; MET; CA9; IGF1R; MAPK1; SRC; KDR; KDR; KDR; PLK1; PLK1; PTK2; AURKB |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | PLK1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| NA: NA | False perceptions | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; DRD2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PLK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; HDAC6 |
| NA: NA | Itching | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |